Loading
Tyra Biosciences, Inc. Stock: price and insider trades · United States
1 insider bought €17k of shares over the last 90 days, the latest filed 11 Sept 2026.
Tyra Biosciences, Inc.: what insiders have been doing
This page follows insider dealings at Tyra Biosciences, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 16 filings came from 8 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €17k) and 8 sales (2 insiders, €6.0M). Taken together, the sales exceed the purchases by €6.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive. Biggest ticket of the year: €4.3M, sold by More Robert J and made public on 25 November 2025.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 16 filings here. The full history, which starts in 2021, counts 7 purchases against 33 sales. The 10-K for the year ended 31 December 2025 shows -119.9 m USD of net income.
The most recent open-market purchase was published on 11 September 2026, 36 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
104
Thresholds
n/a
Buy Volume
€30M
7 ops. · all time
Sell Volume
€13M
33 ops. · all time
Who traded when
BuySaleDaniel Bensen6 sales
Nina S. Kjellson6 sales
RA Capital Management, L.P.4 buys
Gilla Kaplan2 sales
Robert J. More2 sales
Rehan Verjee1 buy
Since the insiders bought
- -24.1%Entry US$25.07 · Close 15 Oct 2026 US$19.04
- +203.1%Entry US$9.59 · Close at T+365 US$29.07
- -38.3%Entry US$14.23 · Close at T+365 US$8.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tyra Biosciences, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$47.45.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.04
Analyst consensus
11 analystsStrong buy
US$29.00Target US$47.45(+149%)US$59.00
Income statement
EBITDA-US$132.2M
Net income-US$119.9M0.0% margin
Valuation
PER (forward)-6.9x
P/Book3.2x
Beta0.75
Balance sheet & cash
Market capUS$1.3B
Total debtUS$5.8M
Free Cash Flow-US$95.3M
Debt / Equity2%
Profitability & ownership
ROE-45.3%
ROA-28.5%
% insiders2.4%
% institutions108.3%
Last declaration on 17 September 2026
Declarations104 total
864 shares@ US$9.1290.0005% mcap0.2% of flowCommon StockSEC:0001193125-26-394738:0
951 shares@ US$9.1290.0006% mcap3.5% of flowCommon StockSEC:0001193125-26-394731:0
2,925 shares@ US$9.1290.0018% mcap100.0% of flowCommon StockSEC:0001193125-26-394734:0
971.894 shares@ US$20.57840.0013% mcap100.0% of flowCommon StockSEC:0001193125-26-389333:0
Canonical exit: 8 Dec 2026 (T+90)
308,379 shares@ US$30.940.49% mcap100.0% of flowCommonSEC144:0001628280-26-045813
14,295 shares@ US$2.258.4% of flowCommon StockSEC:0001193125-26-129239:0
1,463 shares@ US$9.1290.4% of flowCommon StockSEC:0001193125-26-111083:0
1,376 shares@ US$9.1295.1% of flowCommon StockSEC:0001193125-26-111100:0
2,128 shares@ US$31.50183.1% of flowCommon StockSEC:0001193125-26-051534:0
6,983 shares@ US$28.4429.4% of flowCommon StockSEC:0001193125-26-016651:0
1,017 shares@ US$29.08081.4% of flowCommon StockSEC:0001193125-26-016651:1
10,000 shares@ US$25.004.7% of flowCommon StockSEC:0001193125-25-327254:0
8,000 shares@ US$22.64498.5% of flowCommon StockSEC:0001193125-25-320941:0
246,871 shares@ US$20.253695.3% of flowCommon StockSEC:0001193125-25-297551:0
75,633 shares@ US$16.072757.7% of flowCommon StockSEC:0001193125-25-288529:0
1,111 shares@ US$16.00360.8% of flowCommon StockSEC:0001193125-25-284935:0
701 shares@ US$9.1292.5% of flowCommon StockSEC:0001193125-25-206439:0
10 shares@ US$10.350.0% of flowCommon StockSEC:0000950170-25-088602:0
31,307 shares@ US$10.200.4% of flowCommon StockSEC:0001415889-25-017446:0
Canonical exit: 10 Sept 2025 (T+90)
30,000 shares@ US$10.308581.0% of flowCommon StockSEC:0000950170-25-086960:0
186,850 shares@ US$10.192.5% of flowCommon StockSEC:0001415889-25-016759:0
Canonical exit: 7 Sept 2025 (T+90)
997,864 shares@ US$9.6312.5% of flowCommon StockSEC:0001415889-25-015998:0
Canonical exit: 2 Sept 2025 (T+90)
1,241 shares@ US$9.7750.4% of flowCommon StockSEC:0000950170-25-041551:0
1,238 shares@ US$9.7755.2% of flowCommon StockSEC:0000950170-25-041550:0
1,890 shares@ US$13.76112.1% of flowCommon StockSEC:0000950170-25-016385:0
25 of 104 declarations
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a U.S.-listed clinical-stage biotechnology company trading on the Nasdaq Global Select Market under the ticker TYRA. Headquartered in Carlsbad, California, United States, the company was incorporated in 2018 and has built its story around precision medicine with a particular focus on FGFR (fibroblast growth factor receptor) biology. For investors in France, Belgium, and Switzerland, TYRA fits the profile of a development-stage biotech: limited or no commercial revenue today, with valuation driven primarily by pipeline quality, clinical execution, and the probability of regulatory success.
Tyra’s core strategic asset is its proprietary SNÅP discovery platform, an internal drug-design engine intended to generate highly selective and tolerable molecules through iterative optimization. The company’s lead candidate is dabogratinib, an oral and FGFR3-selective inhibitor. This asset sits at the center of Tyra’s development strategy and is being advanced across multiple phase 2 programs. The current clinical roadmap includes studies in pediatric achondroplasia, intermediate-risk non-muscle invasive bladder cancer, and low-grade upper tract urothelial carcinoma. That mix is notable because it ties together oncology and genetically defined diseases through a common biological target, allowing Tyra to potentially build a broader franchise from a single mechanistic thesis.
Read moreShow less
From a competitive standpoint, Tyra operates in a crowded and scientifically demanding field. It competes indirectly with larger oncology-focused biopharma groups and with other companies pursuing FGFR biology or adjacent targeted therapy approaches. Tyra’s potential differentiation lies in the combination of oral dosing, FGFR3 selectivity, and a design philosophy intended to balance potency, safety, and convenience. However, as with most clinical-stage biotech companies, the investment case remains highly binary. Key risks include trial failure, safety limitations, slower-than-expected enrollment, regulatory delays, and the possibility that early clinical signals do not translate into durable efficacy or eventual approval.
Geographically, Tyra’s operations are primarily U.S.-based, with its headquarters in California and its clinical and regulatory activities centered on the United States. Recent company updates in 2025 and 2026 have emphasized continued progress across the dabogratinib program, including advancement of phase 2 trials and the expected sequence of interim data readouts in 2026 and 2027. The company also strengthened its balance sheet through at-the-market equity issuance, improving cash visibility and supporting ongoing development spending. In short, TYRA remains a speculative but focused biotechnology story, with a single lead asset, a proprietary discovery platform, and several near-term clinical catalysts that could materially shape investor sentiment.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
